Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination

Iwata, Hiroka; Kado, Soichiro; Nakaya, Takeo; Kawata, Hirotoshi; Komine, Mayumi; Ohtsuki, Mamitaro

doi:10.1111/1346-8138.16167

Cited by 13 publications

(29 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, we present the case of a patient who exhibited IgAV immediately after receiving the second dose of a COVID-19 vaccine. Although the renal complications of all past IgAV cases were mild [14][15][16][17][18][19][20][21][22], our patient developed severe glomerulonephritis, and it took a considerable amount of time for her recovery despite intensive initial immunosuppressive treatment.…”

Section: Introductionmentioning

confidence: 73%

“…Table 1 summarizes the cases of IgAV after vaccination that we found using a search of the Pubmed and Google Scholar databases as of January 27, 2022. The time to IgAV onset after vaccination ranged from 2 h to 20 days [14][15][16][17][18][19][20][21][22]. Urinary findings suggesting nephritis were mild and transient, and only one biopsy-proven case with mild glomerulonephritis was reported [20].…”

Section: Discussionmentioning

confidence: 99%

“…With the spread of the COVID-19 pandemic and the COVID-19 vaccine programs worldwide, new-onset and relapses of primary kidney disease/vasculitis with kidney involvement that developed after COVID-19 vaccination have recently been reported [7][8][9][10][11][12]. The association between hematuria following a COVID-19 vaccination with the onset or relapse of IgA nephropathy [13] has been attracting attention, and reports of IgAV (Henoch-Schönlein purpura with/without kidney complication) after COVID-19 vaccination are also increasing in number [14][15][16][17][18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review

et al. 2022

View full text Add to dashboard Cite

With the worldwide spread of the COVID-19 vaccine program during the COVID-19 pandemic, the numbers of reported cases with new-onset or relapsed kidney disease/vasculitis such as minimal change nephrotic syndrome, immunoglobulinA (IgA) nephropathy, and IgA vasculitis (IgAV) that developed after COVID-19 vaccination are increasing. We present the case of a 67-year-old Japanese woman who developed IgAV with purpura on her extremities and trunk in the evening of the day that she received the second dose of the Pfizer-BioNTech COVID-19 vaccine. She subsequently presented with acute kidney injury and nephrotic syndrome, and a kidney biopsy performed 14 days after the second vaccination showed diffuse mesangial and endocapillary glomerulonephritis with necrotizing crescent formation, accompanied by IgA deposition. One steroid pulse plus four administrations of a monthly intravenous cyclophosphamide injection were applied, followed by oral azathioprine during oral steroid tapering. Her response to this treatment was unsatisfactory and intractable for some time. Eventually, her renal function improved and nephrotic syndrome was resolved, while microscopic hematuria and proteinuria at ~ 1 g/gCr remained at 6 months post-vaccination. Unlike the previous milder renal-involved IgAV cases following COVID-19 vaccination, our patient's case presented severe glomerulonephritis and took a long time to recover despite intensive initial immunosuppressive treatment.

show abstract

Section: Introductionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Interestingly, of the reviewed cases, two had history of COVID‐19 infection; two had history of IgA vasculitis. 6 , 10 , 11 , 12 , 13 , 14 , 15 A favorable risk–benefit profile of BNT162b2 in rheumatoid arthritis patients, including those on biologics, has been noted. 15 , 40 …”

Section: Resultsmentioning

confidence: 99%

“… 6 , 10 , 11 , 12 , 13 , 14 , 15 A favorable risk–benefit profile of BNT162b2 in rheumatoid arthritis patients, including those on biologics, has been noted. 15 , 40 …”

Section: Resultsmentioning

confidence: 99%

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Abdelmaksoud

Wollina

Temiz

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Currently the most powerful tool in combating the COVID‐19 pandemic is vaccination against SARS‐CoV‐2. A growing percentage of the world's population is being vaccinated. Various vaccines are worldwide on the market. Several adverse reactions have been reported as a part of post‐marketing surveillance of COVID‐19 vaccines. Among the possible adverse events, cutaneous vasculitis has occasionally been reported. We present a narrative review on cutaneous vasculitis related to COVID‐19‐vaccination to summarize clinical findings, histopathology, treatment and outcome. We searched for “COVID vaccine”, “COVID vaccination” AND “cutaneous vasculitis” in PUBMED. Articles in English have been selected, from inception to December 2021, and analyzed for patient's characteristics, type of vaccine, time of appearance of cutaneous vasculitis and clinico‐histopathologic type. Treatment and outcome have also been considered in this narrative review. Two new unpublished cases of ours were added. Cutaneous vasculitis is a rare adverse event to COVID‐19 vaccination. It has been observed with mRNA and adenovirus‐vector vaccines. IgA vasculitis, lymphocytic and ANCA‐associated vasculitis, leukocytoclastic and urticarial vasculitis have been reported. This adverse event can occur after first or second shot. Most cases run a mild to moderate course. Cornerstone of medical treatment are systemic corticosteroids. Complete remission could be achieved in most patients. Vasculitis may not be considered as a contraindication of vaccination, being uncommonly reported and shows a favorable prognosis. The benefit of the vaccination remains high especially for immunocompromised patients. COVID‐vaccine induced vasculitis is important in the differential diagnosis of purpuric and vasculitis disorders.

show abstract

Development of IgA vasculitis after SARS‐CoV‐2 vaccination

Ogura¹,

Morimoto²,

Otsuka³

et al. 2022

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

We report a case of IgA vasculitis that occurred 1 week after COVID‐19 vaccination. Like influenza vaccine, SARS‐CoV‐2 vaccine is considered to have a potential to produce immune complexes with IgA. Given that patients with a history of IgA vasculitis may be flared up following SARS‐CoV‐2 vaccination, individuals with a history of IgA vasculitis should be carefully followed up after receiving the vaccine.

show abstract

Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination

Cited by 13 publications

References 5 publications

Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review

Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Development of IgA vasculitis after SARS‐CoV‐2 vaccination

Contact Info

Product

Resources

About